Wanjun Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wanjun Yu has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Aifeng Liang
Department of Clinical Laboratory QingPu Branch of Zhongshan Hospital Affiliated to Fudan University Shanghai China
1 shared publicationChaoming Mao
Department of Nuclear Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, 212001, China
1 shared publication- Chaoyan Yue
Obstetrics & Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases
1 shared publication Chi Xu
Department of Clinical Laboratory, Shanghai East Hospital, Tongji University School of Medicine, 150 Ji Mo Road, Shanghai, China
1 shared publicationDeyu Chen
Department of Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, 212001, China
1 shared publicationFei Ye
Department of Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, 212001, China
1 shared publication
Latest Publications
- 10 November 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (2) , 1090-1104
The global burden of early‐onset type 2 diabetes (1990–2050): An age–period–cohort analysis of incidence, disparities, and projections
Background: Early‐onset type 2 diabetes mellitus ( T2DM ), diagnosed between 15 and 39 years of age, poses a major public health challenge worldwide. Using data from the Global Burden of Disease Study ( GBD ) 2021, this study aimed to comprehensively assess its global burden, trends, and inequalities from 1990 to 2021, and to project the future burden to 2050. Methods: We analysed age‐standardised incidence ( ASIR ), prevalence ( ASPR ), mortality ( ASMR ), and disability‐adjusted life years ( ASDR ) rates across 204 countries. Analyses included trend analysis, socioeconomic inequality assessment, decomposition, frontier analysis, risk factor analysis, and Bayesian modelling for projections. Results: Between 1990 and 2021, global prevalent cases increased by 222.32%. ASIR , ASPR , and ASDR all rose significantly, with estimated annual percentage changes ( EAPCs ) of 2.45, 2.85, and 2.10, respectively. The burden peaked in middle‐sociodemographic index ( SDI ) regions and South/East Asia, while Oceania had the highest ASRs . The 35–39‐year age group and males bore the highest burden. Socioeconomic inequalities widened, with a 35% increase in mortality disparity affecting low‐income populations. Epidemiological changes were the primary driver of increased incidence and DALYs . High BMI accounted for 44.7%–69.2% of attributable DALYs . We project ASIR will rise to 529.52 per 100 000 by 2050, with 17.14 million new cases. Conclusions: The global burden of early‐onset T2DM rose markedly over the past three decades, with distinct disparities. Persistent inequalities, the dominant role of high BMI , and projected increases highlight an urgent need for targeted prevention in younger populations and high‐risk groups.
- 10 November 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (2) , 1090-1104
The global burden of early‐onset type 2 diabetes (1990–2050): An age–period–cohort analysis of incidence, disparities, and projections
Background: Early‐onset type 2 diabetes mellitus ( T2DM ), diagnosed between 15 and 39 years of age, poses a major public health challenge worldwide. Using data from the Global Burden of Disease Study ( GBD ) 2021, this study aimed to comprehensively assess its global burden, trends, and inequalities from 1990 to 2021, and to project the future burden to 2050. Methods: We analysed age‐standardised incidence ( ASIR ), prevalence ( ASPR ), mortality ( ASMR ), and disability‐adjusted life years ( ASDR ) rates across 204 countries. Analyses included trend analysis, socioeconomic inequality assessment, decomposition, frontier analysis, risk factor analysis, and Bayesian modelling for projections. Results: Between 1990 and 2021, global prevalent cases increased by 222.32%. ASIR , ASPR , and ASDR all rose significantly, with estimated annual percentage changes ( EAPCs ) of 2.45, 2.85, and 2.10, respectively. The burden peaked in middle‐sociodemographic index ( SDI ) regions and South/East Asia, while Oceania had the highest ASRs . The 35–39‐year age group and males bore the highest burden. Socioeconomic inequalities widened, with a 35% increase in mortality disparity affecting low‐income populations. Epidemiological changes were the primary driver of increased incidence and DALYs . High BMI accounted for 44.7%–69.2% of attributable DALYs . We project ASIR will rise to 529.52 per 100 000 by 2050, with 17.14 million new cases. Conclusions: The global burden of early‐onset T2DM rose markedly over the past three decades, with distinct disparities. Persistent inequalities, the dominant role of high BMI , and projected increases highlight an urgent need for targeted prevention in younger populations and high‐risk groups.
- 31 December 2023
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 108 (3) , 116170
Postoperative mediastinitis and sternal osteitis after cardiac surgery caused by Mycoplasma hominis: A case report
- 31 December 2023
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 108 (3) , 116170
Postoperative mediastinitis and sternal osteitis after cardiac surgery caused by Mycoplasma hominis: A case report
- Open Access
- 28 September 2022
- Published by Taylor & Francis in Immunotherapy
- Vol. 14 (16) , 1291-1296
Role of Allogeneic Natural Killer T Cells in the Treatment of a Patient with Gefitinib-Sensitive Lung Adenocarcinoma
Gefitinib has shown good efficacy in patients with EGFR mutation-positive non-small-cell lung cancer, but acquired resistance is inevitable. Here we report a patient with an advanced lung adenocarc... Plain language summary As one of the EGFR tyrosine kinase inhibitors used clinically, gefitinib has achieved good efficacy in patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC)...
- 28 September 2022
- Published by Taylor & Francis in Immunotherapy
- Vol. 14 (16) , 1291-1296
Open AccessRole of Allogeneic Natural Killer T Cells in the Treatment of a Patient with Gefitinib-Sensitive Lung Adenocarcinoma
Gefitinib has shown good efficacy in patients with EGFR mutation-positive non-small-cell lung cancer, but acquired resistance is inevitable. Here we report a patient with an advanced lung adenocarc... Plain language summary As one of the EGFR tyrosine kinase inhibitors used clinically, gefitinib has achieved good efficacy in patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC)...